Sutro Biopharma (STRO) - Net Assets
Based on the latest financial reports, Sutro Biopharma (STRO) has net assets worth $-103.32 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($194.46 Million) and total liabilities ($297.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STRO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-103.32 Million |
| % of Total Assets | -53.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | -152.44% |
| 10-Year Change | N/A |
| Growth Volatility | 172.15 |
Sutro Biopharma - Net Assets Trend (2016–2025)
This chart illustrates how Sutro Biopharma's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Sutro Biopharma.
Annual Net Assets for Sutro Biopharma (2016–2025)
The table below shows the annual net assets of Sutro Biopharma from 2016 to 2025. Also explore how fast is Sutro Biopharma growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-132.45 Million | -396.97% |
| 2024-12-31 | $44.60 Million | -70.20% |
| 2023-12-31 | $149.65 Million | -31.05% |
| 2022-12-31 | $217.05 Million | -14.06% |
| 2021-12-31 | $252.56 Million | -23.94% |
| 2020-12-31 | $332.05 Million | +239.56% |
| 2019-12-31 | $97.79 Million | -25.66% |
| 2018-12-31 | $131.54 Million | +220.68% |
| 2017-12-31 | $-109.00 Million | -19.91% |
| 2016-12-31 | $-90.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sutro Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 88263200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | % |
| Other Comprehensive Income | $19.00K | % |
| Other Components | $845.48 Million | % |
| Total Equity | $-132.45 Million | 100.00% |
Sutro Biopharma Competitors by Market Cap
The table below lists competitors of Sutro Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metalfrio Solutions S.A
SA:FRIO3
|
$256.73 Million |
|
Richmond Mutual Bancorporation Inc
NASDAQ:RMBI
|
$256.76 Million |
|
Wam Microcap Ltd
AU:WMI
|
$256.79 Million |
|
Youlchon Chem
KO:008730
|
$256.80 Million |
|
Gaon Group Ltd
TA:GAGR
|
$256.63 Million |
|
Jackson Acquisition Company II
NYSE:JACS
|
$256.52 Million |
|
Aldel Financial II Inc. Class A Ordinary Shares
NASDAQ:ALDF
|
$256.52 Million |
|
Burgenland Holding Aktiengesellschaft
VI:BHD
|
$256.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sutro Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 44,601,000 to -132,452,000, a change of -177,053,000 (-397.0%).
- Net loss of 191,086,000 reduced equity.
- Other comprehensive income decreased equity by 20,000.
- Other factors increased equity by 14,053,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-191.09 Million | -144.27% |
| Other Comprehensive Income | $-20.00K | -0.02% |
| Other Changes | $14.05 Million | +10.61% |
| Total Change | $- | -396.97% |
Book Value vs Market Value Analysis
This analysis compares Sutro Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-2060.31 | $15.48 | x |
| 2017-12-31 | $-15.58 | $15.48 | x |
| 2018-12-31 | $57.53 | $15.48 | x |
| 2019-12-31 | $42.59 | $15.48 | x |
| 2020-12-31 | $10.19 | $15.48 | x |
| 2021-12-31 | $54.76 | $15.48 | x |
| 2022-12-31 | $42.78 | $15.48 | x |
| 2023-12-31 | $24.87 | $15.48 | x |
| 2024-12-31 | $5.81 | $15.48 | x |
| 2025-12-31 | $-15.59 | $15.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sutro Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -186.45%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-77.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 2.85% | 0.86x | 0.00x | $10.79 Million |
| 2017 | 0.00% | -38.05% | 1.27x | 0.00x | $-8.79 Million |
| 2018 | -26.85% | -91.93% | 0.17x | 1.70x | $-48.47 Million |
| 2019 | -57.00% | -130.44% | 0.27x | 1.60x | $-65.52 Million |
| 2020 | -9.68% | -75.20% | 0.11x | 1.19x | $-65.33 Million |
| 2021 | -41.79% | -170.55% | 0.18x | 1.35x | $-130.79 Million |
| 2022 | -54.92% | -175.89% | 0.17x | 1.87x | $-140.91 Million |
| 2023 | -71.36% | -69.47% | 0.33x | 3.15x | $-121.76 Million |
| 2024 | -509.99% | -366.62% | 0.16x | 8.68x | $-231.92 Million |
| 2025 | 0.00% | -186.45% | 0.59x | 0.00x | $-177.84 Million |
Industry Comparison
This section compares Sutro Biopharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sutro Biopharma (STRO) | $-103.32 Million | 0.00% | N/A | $256.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more